Skip to main content
. 2016 May 24;6:26456. doi: 10.1038/srep26456

Figure 8. MLN9708 inhibits doxorubicin (Dox)-induced IκBα degradation in breast cancer cells.

Figure 8

(a–h) Breast cancer cells (T-47D, MCF7, MDA-MB-361, SK-BR-3, HCC1954, MDA-MB-468, MDA-MB-231, and BT-549) were treated with Dox (20 μM) alone or in combination with MLN9708 (1 μM) for 2 h, 3 h, or 4 h. Untreated cells were used as controls. Then whole-cell lysates were subjected to SDS-PAGE and were immunoblotted with antibodies against p-JNK, JNK, p-p38, p38, and IκBα. β-actin was used as a loading control.